MedTrace Logo

Trimethylamine N-oxide in Myocardial Infarction

NCT03418285 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 112

Last updated 2018-02-05

No results posted yet for this study

Summary

Trimethylamine-N-oxide (TMAO) is produced from the metabolism of gut microbiota and is reportedly pro-atherogenic and associated with cardiovascular events. The purpose of this study is to investigate the sequential change in TMAO levels by current optimal secondary prevention therapies in patients with ST-elevation acute myocardial infarction (STEMI) and the clinical impact of TMAO levels on the progression of atherosclerosis and subsequent cardiovascular events.

Conditions

Sponsors & Collaborators

  • Yokohama City University Medical Center

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-01
Primary Completion
2018-01-01
Completion
2018-01-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03418285 on ClinicalTrials.gov